Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
Yongchang Zhang(Central South University), Nong Yang(Central South University)
Cited by 19
Related Papers
The NF-κB p65/miR-23a-27a-24 cluster is a target for leukemia treatment
|Oncotarget|2015|21
Mast cells induce epithelial-to-mesenchymal transition and migration in non-small cell lung cancer through IL-8/Wnt/β-catenin pathway
|Journal of Cancer|2019|21
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
|The Journal of Experimental Medicine|2024|21
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer
|Communications Medicine|2022|20
Expert consensus on treatment for stage III non‐small cell lung cancer
|Medicine Advances|2023|18